The treatment landscape for systemic lupus erythematosus (SLE) has changed significantly in recent years thanks to cellular immunotherapies targeting pathogenic B-cells. CD19-directed autologous CAR T-cell therapy induced remission in patients with severe refractory SLE. These innovations address a large global disease burden, with more than 3.4 million people affected worldwide. In an Asia-Pacific cohort study, at least 14% of patients had severe disease. The article comments on the investigation of CAR NK-cell therapy for refractory lupus.[1]